Bristol Myers Squibb (BMY) vs peers
BMY's EV/Sales is 3.2x, compared with 4.3x at the middle of 5 peers.
Pharmaceuticals. Updated .
| Stock | EV/Sales | Own 5-year rank |
|---|---|---|
| BMYBristol Myers Squibb | 3.2x | 42% |
| LLYLilly (Eli) | 14.8x | 49% |
| MRKMerck & Co. | 6.3x | 99% |
| ZTSZoetis | 4.3x | 8% |
| PFEPfizer | 3.5x | 71% |
| VTRSViatris | 2.3x | 99% |
How to read this comparison
Up to eight covered companies in the same industry, largest market value first.
EV/Sales divides enterprise value (stock market value plus debt, less cash) by revenue from the previous twelve months. The middle peer reading excludes BMY and unavailable values.
Own 5-year rank compares each stock with its available weekly readings within the last five years. At least 26 usable weeks are required. A rank of 20% means its current multiple is above 20% of its past readings. It is not a rank against the other stocks in this table.
Dates show data updates; the latest available weekly observation can differ between stocks. Different growth rates, margins and financial risks can explain different multiples. Missing or non-positive denominators are left unranked.